967 related articles for article (PubMed ID: 22279576)
1. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Denman CJ; Senyukov VV; Somanchi SS; Phatarpekar PV; Kopp LM; Johnson JL; Singh H; Hurton L; Maiti SN; Huls MH; Champlin RE; Cooper LJ; Lee DA
PLoS One; 2012; 7(1):e30264. PubMed ID: 22279576
[TBL] [Abstract][Full Text] [Related]
2. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
3. Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function.
Zhang C; Kadu S; Xiao Y; Johnson O; Kelly A; O'Connor RS; Lai M; Kong H; Srivatsa S; Tai V; Greenblatt E; Holmes M; Riley JL; June CH; Sheppard NC
Cancer Immunol Res; 2023 Nov; 11(11):1524-1537. PubMed ID: 37649085
[TBL] [Abstract][Full Text] [Related]
4. Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21.
Somanchi SS; Lee DA
Methods Mol Biol; 2016; 1441():175-93. PubMed ID: 27177666
[TBL] [Abstract][Full Text] [Related]
5. Expansion, purification, and functional assessment of human peripheral blood NK cells.
Somanchi SS; Senyukov VV; Denman CJ; Lee DA
J Vis Exp; 2011 Feb; (48):. PubMed ID: 21339714
[TBL] [Abstract][Full Text] [Related]
6. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21.
Kweon S; Phan MT; Chun S; Yu H; Kim J; Kim S; Lee J; Ali AK; Lee SH; Kim SK; Doh J; Cho D
Front Immunol; 2019; 10():879. PubMed ID: 31105701
[No Abstract] [Full Text] [Related]
7. Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.
Wang W; Erbe AK; Alderson KA; Phillips E; Gallenberger M; Gan J; Campana D; Hank JA; Sondel PM
Cancer Immunol Immunother; 2016 Sep; 65(9):1047-59. PubMed ID: 27392940
[TBL] [Abstract][Full Text] [Related]
8. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
[TBL] [Abstract][Full Text] [Related]
9. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
10. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells.
Liu E; Ang SOT; Kerbauy L; Basar R; Kaur I; Kaplan M; Li L; Tong Y; Daher M; Ensley EL; Uprety N; Nunez Cortes AK; Yang RZ; Li Y; Shaim H; Reyes Silva F; Lin P; Mohanty V; Acharya S; Shanley M; Muniz-Feliciano L; Banerjee PP; Chen K; Champlin RE; Shpall EJ; Rezvani K
Front Immunol; 2021; 12():626098. PubMed ID: 33717142
[TBL] [Abstract][Full Text] [Related]
11. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.
Granzin M; Soltenborn S; Müller S; Kollet J; Berg M; Cerwenka A; Childs RW; Huppert V
Cytotherapy; 2015 May; 17(5):621-32. PubMed ID: 25881519
[TBL] [Abstract][Full Text] [Related]
12. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
Zhang H; Cui Y; Voong N; Sabatino M; Stroncek DF; Morisot S; Civin CI; Wayne AS; Levine BL; Mackall CL
J Immunother; 2011 Mar; 34(2):187-95. PubMed ID: 21304401
[TBL] [Abstract][Full Text] [Related]
13. IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential.
Lehmann D; Spanholtz J; Sturtzel C; Tordoir M; Schlechta B; Groenewegen D; Hofer E
PLoS One; 2014; 9(1):e87131. PubMed ID: 24498025
[TBL] [Abstract][Full Text] [Related]
14. Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.
Thangaraj JL; Phan MT; Kweon S; Kim J; Lee JM; Hwang I; Park J; Doh J; Lee SH; Vo MC; Chu TH; Song GY; Ahn SY; Jung SH; Kim HJ; Cho D; Lee JJ
Cancer Immunol Immunother; 2022 Mar; 71(3):613-625. PubMed ID: 34282497
[TBL] [Abstract][Full Text] [Related]
15. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
16. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
[TBL] [Abstract][Full Text] [Related]
17. Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-γ Production, and Lifespan.
Streltsova MA; Erokhina SA; Kanevskiy LM; Grechikhina MV; Kobyzeva PA; Lee DA; Telford WG; Sapozhnikov AM; Kovalenko EI
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669565
[TBL] [Abstract][Full Text] [Related]
18. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and functional characterisation of locally produced natural killer cells ex vivo expanded with the K562-41BBL-mbIL21 cell line.
Shman TV; Vashkevich KP; Migas AA; Matveyenka MA; Lasiukov YA; Mukhametshyna NS; Horbach KI; Aleinikova OV
Clin Exp Med; 2023 Oct; 23(6):2551-2560. PubMed ID: 36527513
[TBL] [Abstract][Full Text] [Related]
20. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
